Brooke Janas
Women's Health · North Platte, NENPI 1578017604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 47.0% of the total.
Across 150 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$244
- Pfizer$138
- Ascend Therapeutics US, LLC$126
- Lilly USA, LLC$119
- Novo Nordisk$73
- plus $635 from 21 others
What the payments were for
- Food & beverage$2,42897%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,181 |
| Astellas Pharma US Inc | 9 | $244 |
| Pfizer | 6 | $138 |
| Ascend Therapeutics US, LLC | 6 | $126 |
| Lilly USA, LLC | 7 | $119 |
| Novo Nordisk | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| IBSA Pharma Inc. | 3 | $60 |
| Myovant Sciences Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $48 |
| Lundbeck LLC | 3 | $44 |
| AstraZeneca | 3 | $43 |
| Bayer | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Biogen | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Alkermes, Inc. | 1 | $24 |
| Organon | 3 | $21 |
| Biowound Solutions, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Vivus LLC | 1 | $17 |
| Urovant Sciences Inc | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $4 |
How this compares
$2,514 in reported general payments places this provider in the 80th percentile of 60 women's health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $11,063 |
| Celecoxib | 12 | $768 |
| Estradiol | 11 | $683 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $391 |
| Sertraline Hcl | 22 | $338 |
| Omeprazole | 27 | $283 |
| Metoprolol Succinate | 11 | $272 |
| Pantoprazole Sodium | 11 | $253 |
| Losartan Potassium | 16 | $244 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $192 |
| Atorvastatin Calcium | 16 | $190 |
| Levothyroxine Sodium | 16 | $181 |
| Lisinopril | 20 | $120 |
| Montelukast Sodium | 13 | $115 |
| Metformin Hcl | 13 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $73 | $11,06313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 60 women's health providers in Nebraska.
Other women's health in North Platte
- Rylee HorsleyKearney$125K
- Leslie DvorakOmaha$65K
- Sonia SublettOmaha$8K
- Jessica SiemersOmaha$4K
- Emily BlanchardOmaha$3K
- Allison WhiteLincoln$3K
- Terra VejraskaLincoln$3K
- Jackie OdenLincoln$3K
- Lisa PatrickOmaha$3K
- Audrey GrayLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.